PharmaEngine (4162) — Cash Flow Reinvestment Rate
PharmaEngine (4162) has a Cash Flow Reinvestment Rate of 8.59x as of September 2025, reinvesting NT$455.53 Million (capex NT$115.00K plus investments NT$-455.41 Million) from operating cash flow of NT$53.01 Million. Check 4162 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
PharmaEngine Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for PharmaEngine across 12 annual periods. Explore PharmaEngine cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for PharmaEngine (2011–2024)
Year-by-year capital reinvestment analysis for PharmaEngine. For live market cap and broader valuation context, see market cap of PharmaEngine.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.25x | NT$116.09 Million | NT$456.73 Million | NT$1.42 Million | ▼ -92.4% |
| 2023 | 3.33x | NT$856.44 Million | NT$256.97 Million | NT$958.00K | ▲ +258.3% |
| 2022 | 0.93x | NT$187.92 Million | NT$202.01 Million | NT$3.94 Million | ▲ +721.8% |
| 2021 | 0.11x | NT$105.23 Million | NT$929.67 Million | NT$229.00K | ▼ -99.6% |
| 2020 | 27.26x | NT$1.77 Billion | NT$64.77 Million | NT$608.00K | ▲ +2267.7% |
| 2019 | 1.15x | NT$18.51 Million | NT$16.08 Million | NT$208.00K | ▲ +42.4% |
| 2018 | 0.81x | NT$602.36 Million | NT$745.23 Million | NT$510.00K | ▲ +8.1% |
| 2016 | 0.75x | NT$650.89 Million | NT$870.38 Million | NT$1.15 Million | ▼ -87.7% |
| 2015 | 6.10x | NT$2.73 Billion | NT$447.99 Million | NT$11.80 Million | ▲ +841249.6% |
| 2014 | 0.00x | NT$95.00K | NT$131.09 Million | NT$95.00K | ▼ -40.1% |
| 2012 | 0.00x | NT$83.00K | NT$68.64 Million | NT$83.00K | ▼ -58.7% |
| 2011 | 0.00x | NT$806.00K | NT$275.49 Million | NT$806.00K | — |